2Rossing K, Schjoedt KJ, Jensen BR, et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria[J]. Kidney Int,2005,68(6):1190-1198.
3Sasso FC,Carbonara O,Persico M,et al. Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetie patients independently of hypertension: a randomized doubleblind placebo-controlled crossover study [J]. Diabetes Care, 2002,25(8):1909-1913.
4Cetinkalp SS, Karadeniz MM, Erdogan MA, et al. Short-term effects ofirbesartan treatment on microalbuminuria in patients with normotensive type 2 diabetes[J]. Saudi Med J, 2008,29 (10):1414-1418.
5Leidig M,Bambauer R,Kirchertz EJ ,et al. Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study)[J]. Clin Nephrol,2008,69(6) :425-432.
6Ofili EO, Cable G, Neutel J M, at al. Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women:the inclusive trial[J]. J Womens Health (Larchmt), 2008,17(6) :931-938.
7Deepa PR, Varalakshmi P. The cytoprotective role of a low-molecular-weight heparin fragment studied in an experimental model of glomerulotoxicity[J]. Eur J Pharmacol, 2003,478(2/ 3):199-205.
8Rajeswari A, Varalakshmi P. Low molecular weight heparin protection against oxalate-induced oxidative renal insult [J]. Clin Chim Acta,2006,370(1/2):108-114.
9Nasstrom B,Stegmayr B,Gupta J ,et al. A single bolus of a low molecular weight heparin to patients on haemodialysis depletes lipoprotein lipase stores and retards triglyceride clearing [J]. Nephrol Dial Transplant, 2005,20 (5) : 1172.
4Sasso F C, Carbonara 0,Persico M, et al. Irbes art an reduces the albu-min excretion rate in microalbuminuric: type-2 diabetie patients in de-pendentiy of hypertension: a randomized double blind placebo -(con-trolled cross over study [J] . Diabetes Care, 2002,25(8):1909-1913.
5Leidig M, Bamhauer R, Kirchertz E J, et al. Efficacy, safety and toiera-bility of valsarl an 80 mg compared to irbesart an 150 mg in hyperten-sive patients on long-term hemodialysis (VALID study)[J]. Clin Nephrol,2008, 69(6):425-432.
6Rajeswari A, Varalakshmi P. Low molecular weight heparin protection against oxalat e-induced oxidative renal in suit [J] .Clin Chim Acta, 2006, 370(1/2):108-114.
9Ratanawongsa N,Handley MA,Quan J,et al.Quasi-experimental trial of diabetes SelfManagement Automated and Real-Time Telephonic Support(SMARTSteps)in a Medicaid managed cara plan:study protuocol[].BMC Health Sarv Res.2012
10Parati G,Bilo G,Ochoa JE.Benefits of tight blood pressure control in di-abetic patients with hypertension:importance of early and sustained im-plementation of effective treatment strategies[].Diabetes Care.2011
